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Summary
Objective: According to recent reports, the synovial membrane may contain mesenchymal stem cells with the potential to differentiate into
chondrocytes under appropriate conditions. In order to assess the usefulness of synovium-derived progenitor cells for the purposes of
cartilage tissue engineering, we explored their requirements for the expression of chondrocyte-speciﬁc genes after expansion in vitro.
Design: Mesenchymal progenitor cells were isolated from the synovial membranes of bovine shoulder joints and expanded in two-dimensions
on plastic surfaces. They were then seeded either as micromass cultures or as single cells within alginate gels, which were cultured in serum-
free medium. Under these three-dimensional conditions, chondrogenesis is known to be supported and maintained. Cell cultures were
exposed either to bone morphogenetic protein-2 (BMP-2) or to isoforms of transforming growth factor-b (TGF-b). The levels of mRNA for Sox9,
collagen types I and II and aggrecan were determined by RT-PCR.
Results: When transferred to alginate gel cultures, the ﬁbroblast-like synovial cells assumed a rounded form. BMP-2, but not isoforms of TGF-b,
stimulated, in a dose-dependent manner, the production of messenger RNAs (mRNAs) for Sox9, type II collagen and aggrecan. Under optimal
conditions, the expression levels of cartilage-speciﬁc genes were comparable to those within cultured articular cartilage chondrocytes.
However, in contrast to cultured articular cartilage chondrocytes, synovial cells exposed to BMP-2 continued to express the mRNA for a1(I)
collagen.
Conclusions: This study demonstrates that bovine synovium-derived mesenchymal progenitor cells can be induced to express chondrocyte-
speciﬁc genes. However, the differentiation process is not complete under the chosen conditions. The stimulation conditions required for full
transformation must now be delineated.
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SocietyIntroduction
Because terminally differentiated adult cells are of limited use
for tissue engineering,many researchers have tried to isolate
multipotent progenitor cells, which have been considered
promising. Multipotent progenitor cells from adult bone
marrowhave thepotential todifferentiate intospeciﬁcsomatic
cells1. Since then, many researchers have utilized stem cells
from several adult tissues for various applications2e6.
For articular cartilage repair, different kinds of grafting
methods, such as the use of osteochondral and periosteal
tissue and implantation of autologous chondrocytes, have
been used in clinical practice7. Unfortunately, there are no
methods as of yet that produce consistent and successful
results8. In recent years, chondrogenic progenitor cells that
might be used for cartilage repair have been identiﬁed in
variousadult tissues: bonemarrow1,6, periosteum9, fat10, and
synovialmembrane11e13. By treating these cells in 3Dculture
with suitable agents, such as dexamethasone, transforming
growth factor-b (TGF-b) and bone morphogenic proteins
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Received 30 June 2004; revision accepted 6 February 2005.527(BMPs), activation of chondrogenesis has been demonstrat-
ed14. In the ideal environment, the progenitor cells assume
chondrocyte-like characteristics, such as a rounded shape,
and synthesize glycosaminoglycans (GAGs), collagen type II
and aggrecan, which are typical extracellular matrix compo-
nents of hyaline cartilage.
One of the very promising tissue sources for chondrogenic
progenitor cells to induce articular cartilage repair12,15 seems
to be synovium13,15. Synovial tissue contains various cell
types, such as the pseudoepithelial lining cells (types A and
B)16, those within the connective tissue at subepithelial and
perivascular locations, and endothelial cells (in blood
capillaries)17. Moreover, it is known from clinical pathology
that primary chondromatous tumors can form within this
tissue18, which further illustrates the potential of some
subpopulations of synovial cells to transform into chondro-
cytes and to form cartilage-like tissue. In addition, the
example of rheumatoid pannus shows that synovial mem-
brane contains chondrocyte-like cells19. Experimentally,
synovial cells can be induced tomigrate into partial-thickness
articular cartilage defects, therein to proliferate and sub-
sequently to deposit a scar-like tissue12 and differentiate fully
into chondrocytes following appropriate stimulation15,20.
There are some in-vitro experiments described in the
literature that show the chondrogenic activity of progenitor
cells isolated from synovial membranes. Such cells undergo
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plates13. It has also been reported that explants from rabbit
synovial tissues started to express collagen type II if treated
with TGF-b1 in vitro11. Recently, progenitor cells which have
chondrogenic, myogenic and adipogenic potential were
identiﬁed in adult human synovial membrane21.
The quality and nature of the culturing conditions adopted
are of key importance in the induction of chondrogenic
differentiation. It is well known, for example, that if chon-
drocytes are cultured under 2D conditions, they start to
dedifferentiate and to lose their chondrogenic phenotype and
activity22. However, when chondrocytes are cultured under
3D conditions, they readily recover a chondrogenic pheno-
type and metabolic activity following a redifferentiation pro-
cess23. Therefore, 3D culture conditions are essential to
maintain the chondrogenic potential24. And for chondrocytes
or chondrogenic progenitor cells, particularly alginate hydro-
gel has previously been identiﬁed to maintain the chondro-
genic phenotype9,11.
In the present study, we cultured and expanded synovial
cells under 2D conditions for the selection of chondrogenic
precursor cells, and subsequently cultured these under 3D
conditions in adeﬁnedserum-freemedium25. Thegoalwas to
establish thoroughly deﬁned culture conditions that allow the
synovial progenitor cells to assumeagene-expression proﬁle
which resembles that of articular chondrocytes. For the
initiation of the process of chondrogenic differentiation,
various culture conditionsandgrowth factorswereexamined.
For 3D cultures, alginate hydrogel was used and as growth
factors TGF-bs and BMP-2 were tested. The expression
proﬁle of chondrocyte-speciﬁc genes was monitored by real-
time PCR, and the accumulation of GAGs was also
measured. Cellular morphology and the distribution of ﬁbrillar
collagen were visualized by histological examination. All
parameters were quantitatively compared to those obtained
from articular chondrocytes isolated from the same joint, and
cultured under the same conditions.
Methods
PREPARATION OF SYNOVIAL TISSUE AND CELL CULTURE
Pieces of synovial membrane were obtained aseptically
from the shoulder joints of 2- to 4-year-old adult cows within
24 h of death. Tissue samples were washed with phosphate-
buffered saline (PBS) [pH 7.4] containing gentamycin (50 mg/
ml) and incubated in high-glucose Dulbecco’s modiﬁed
Eagle’s medium (DMEM) [Life Technologies, Basel, Switzer-
land] containing 0.35 mM proline and 50 mg/ml gentamycin,
for 3 h. Then, tissues were minced using a razor blade and
digested with 1% pronase (Roche Diagnostics, Basel,
Switzerland) in the medium for 1 h and with 0.14%
collagenase (Life Technologies, Basel, Switzerland) over-
night at 37(C. Cells were washed with PBS and subsequen-
tially ﬁltered through 120 mm and 20 mm nylon ﬁlters
(Millipore AG, Volketswil, Switzerland) to remove the un-
digested tissues. Cells were resuspended for expansion and
selection in high-glucoseDMEMwith 10% fetal bovine serum
(FBS) [Sigma, St Louis, USA], 0.35 mM proline, 20 mg/ml
ascorbate, 1 mM cysteine, 1 mM pyruvate and 50 mg/ml
gentamycin21,26.
Isolated cells were cultured in 100 mm cell culture plates
(Falcon, Bedford, MA, USA) at 37(C in an incubator with 5%
CO2. The culture medium was replaced every 2e3 days.
After 7e10 days, conﬂuent cells were washed with PBS
and trypsinized with trypsin-ethylenediamine tetra-acetic
acid (EDTA) solution (0.25% trypsin, 1 mM EDTA; LifeTechnologies). Cells were replated in culture dishes at
a 1:3 dilution rate to obtain the appropriate subculture cell
system.
MICROMASS CULTURE
For passage one, cells from these subcultures were
trypsinized and resuspended in culture medium to a concen-
tration of 2! 107 cells/ml. Twenty microliters of cell suspen-
sion were deposited per well in 24-well cell culture plates
(Falcon, Bedford, MA, USA) and incubated for 4 h at 37(C in
the cell culture incubator for adherence of the cells. Then,
1 ml per well of serum-free medium [high-glucose DMEM
with 0.35 mM proline, 50 mg/ml gentamycin, and 0.01%
bovine serum albumin (BSA)]25 was added containing
20 ng/ml of one of the following growth factors: TGF-b1,
TGF-b2, TGF-b3 (Sigma, St. Louis, USA) or BMP-2 (kindly
supplied by Wyeth, Massachusetts, USA). Respectively,
control cells were cultured in the same medium without
growth factors. Cells were cultured at 37(Cand 5%CO2 for 1
weekwith a change ofmedium every 2 days. Cells were ﬁxed
with 2.5% paraformaldehyde and washed with PBS. For
alcian blue staining, cells were incubated with alcian blue
solution (1% alcian blue 8GX in 3% acetic acid, pH 2.5) for
1 h. After staining, cells were washed with PBS and
subjected to optical examination.
THREE-DIMENSIONAL CELL CULTURE IN ALGINATE DISKS
For cell culture under 3D conditions, alginate disks were
prepared by following the protocol described by Wong
et al.27. Brieﬂy, 2% alginate solutions were prepared by
mixing 1% Keltone LV alginate (Kelko Co., San Diego, CA,
USA) and 1%Alginate LGV (PronovaBiomedical, Norway) in
0.9% NaCl. Cells from passage one were pelleted and
suspended in alginate at a concentration of 4! 106 cells/ml.
Alginate solution containing cells was injected into an
ethanol-sterilized, custom-designed mold encompassing
a 22 mm diameter! 2 mm cylindrical space. Alginate was
polymerized for 30 min by placing the mold in a gelation
solution containing 50 mM CaCl2 and 0.9% NaCl. Gels were
cut with sterile dermal punches (outer diameter 6 mm, Stiefel
Laboratorium AG, Winterthur, Switzerland) to create a small
alginate disk (5.5 mm in diameter! 2 mm in height).
Alginate disks were cultured in high-glucose DMEM
containing 1% ITSCPremix (Collaborative Biomedical
Products), insulin (6.25 mg/ml), transferrin (6.25 mg/ml),
selenous acid (6.25 mg/ml), linoleic acid (5.35 mg/ml), BSA
(37.5 mg/ml), pyruvate (1 mM) and ascorbate (37.5 mg/
ml)14,25. For BMP-2 treatment, different concentrations of
BMP-2 were added from a 20 mg/ml stock solution to the
culture medium, which was changed every 2e3 days. A
possible enhancement of the chondrogenic effect by
dexamethosone (108 M) was also investigated.
CELL HARVEST AND MEASUREMENT OF GAGs
After the desired culture period, cells in the alginate disks
were harvested by solubilizing the alginate gels in 55 mM
sodium citrate in 0.9% NaCl for 45 min at 37(C. Cells were
collected by centrifugation at 3500 rpm for 10 min. For
measurement of glycosaminoglycan (GAG) content, cell
pellets and supernatantswere incubatedwith papain solution
(0.56 mg/ml) in 50 mM sodium phosphate with 10 mM EDTA
and 2 mM L-cysteine (pH 6.5) overnight at 65(C. After
cooling to room temperature, 20 ml of digested solutions were
incubated with 400 ml of color reagent from the Blyscan kit
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were centrifugedat 13,000 rpm for 10 min. After removing the
supernatants, pellets containing the GAG-color reagent
complex were dissolved in 400 ml of dissociation reagent
from the kit by incubating at 37(C for 1 h. Optical density at
590 nm was measured using a microtiter plate reader. The
GAG contents were calculated from a standard curve pre-
pared using puriﬁed chondroitin sulfate in the kit.
RNA EXTRACTION AND REVERSE TRANSCRIPTION REACTION
Alginate disks were solubilized with sodium citrate/NaCl
buffer and cells were collected by centrifugation as described
above. After washing the cells with PBS once, RNA was
extracted using an RNA extraction kit (Qiagen, Basel,
Switzerland). The extracted RNA was dissolved in 50 ml of
RNase-free distilled water and stored at 80(C until use.
cDNA was synthesized from 500 ng of RNA using TaqMan
Reverse Transcription Reagents (Applied Biosystems, Sera-
ing, Belgium).
DESIGN OF PRIMERS AND PROBES FOR REAL-TIME PCR
Primers and probes for bovine type I collagen [a1(I)], type II
collagen (a1(II)), aggrecan, andSox9were designedwith the
Primer Express software (PerkineElmer Applied Biosys-
tems, Foster City, CA, USA). As an internal control, 18s rRNA
primer and probe sets were used, which are available from
the company. The sequenceof the speciﬁcbovine geneswas
downloaded from the Gene Bank database. In the center of
each probe sequence, an exon-exon junction was placed to
avoid non-speciﬁc ﬂuorescent emission derived from con-
taminating genomic DNA. The nucleotide sequences of the
primers and probes are shown in Table I. Primers were
purchased from Microsynth (Balgach, Switzerland). The
probes were labeled with carboxyﬂuorescein (FAM) at the
5# end and with N,N,N#,N#-tetramethyl-6-carboxyrhodamine
(TAMRA) at the 3# end. They were obtained from Perkin-
Elmer Applied Biosystems (Seraing, Belgium). The concen-
trations of the primers and probes were used following the
company’s User Bulletin No. 2; for primers: 900 nM, for
probes: 300 nM.
REAL-TIME QUANTITATIVE PCR
Quantiﬁcation of mRNAs was performed by real-time
quantitative PCR with a Perkin-Elmer ABI Prism 7700sequence detection system. PCR was performed with
AmpliTaq Gold polymerase (Perkin-Elmer ABI) using
20 ng of cDNA per reaction. The cycle threshold (Ct) values
for 18s rRNA and the mRNAs of interest were compared
and calculated by sequence detector software (Perkin-
Elmer ABI). Relative transcript levels were calcu-
lated as xZ2DDCt , where DDCtZDEDC and
DEZCt experimentalCt 18s rRNA; DCZCt controlCt 18s rRNA.
For comparison, the Ct-value of the non-treated sam-
ple was used as a normalized control in most of the
experiments.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Immediately after culture, alginate disks were ﬁxed in 4%
paraformaldehyde buffered with 0.1 M sodium cacodylate
(pH 7.4) containing 10 mMCaCl2 for 4 h at room temperature
and then washed overnight at 4(C in 0.1 M cacodylate buffer
(pH7.4) containing 50 mMBaCl2. Thedisksweredehydrated
through ethanol and xylene, embedded in parafﬁn and 5-mm
sections were prepared.
For histological evaluation, sections were stained with
Toluidine Blue. Additional sections were used for the im-
munohistochemical analysis with antibodies against type II
collagen.
Parafﬁn-embedded sections were deparafﬁnized using
xylene and rehydrated in ethane solutions. Endogenous
peroxidase activity was blocked by a 20-min incubation in 1%
H2O2 in methanol. After one 5-min wash with Tris buffered
saline (TBS), the sections were pretreated with 20 mU/ml
chondroitinase ABC (Sigma, St Louis, MO, USA) in TBS
buffer for 1 h at room temperature. Residual enzyme was
removed with one 5-min wash with TBS, and 1% BSA was
placed on the section for 15 min to block non-speciﬁc
background staining.
Slides were incubated with primary antibodies [rabbit
antibody against bovine collagen type II (Biodesign, Saco,
ME, USA)], diluted 1:100 in TBS containing 1% bovine
albumin (Serva, Heidelberg, Germany), for 1 h at room
temperature. Slides were then washed three times with TBS,
incubated at room temperature for 45 min with horseradish-
peroxidase-conjugated secondary antibody [goat antibody
to rabbit IgG (Biodesign, Saco, ME, USA)], diluted 1:100 in
TBS/1% BSA. For positive and negative controls, normal
bovine articular cartilage was used. Negative control
sections did not receive the primary antibody. All incubations
were performed in humidiﬁed chambers. Peroxidase activityTable I
Primers and probes used for real-time PCR. Primers and probes with FAM/TAMRA are represented
Gene Sequence Amplicon size Accession no.
Type I col* Forward ACATGCCGAGACTTGAGACTCA 86 AB008683
Probe CCACCCAGA(G/A)TGGAGCAGCGGTTACTACTG
Reverse GCATCCATAGTACATCCTTGGTTAGG
Type II col* Forward AGCAGGTTCACATATACCGTTCTG 73 X02420
Probe CCGGT(A/G)TGTTTCGTGCAGCCATCCT
Reverse CGATCATAGTCTTGCCCCACTT
Aggrecan* Forward CAGCCAGGCCACCCTAGAG 74 U76615
Probe ATGGAACACGATGCCTTT(C/T)ACCACGA
Reverse GGGTGTAGCGCGTGGAGAT
Sox9* Forward ACGCCGAGCTCAGCAAGA 71 AF278708
Probe CGTTCAG(A/C)AGTCTCCAGAGCTTGCCCA
Reverse CACGAACGGCCGCTTCT
*Mixtures were made based on mismatches between the bovine and human sequences.
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Louis, MO, USA) as substrate. Sectionswere counterstained
with Mayer’s hematoxylin.
STATISTICAL ANALYSIS
Each experiment was repeated 3 to 4 times. On each
separate occasion, the cells were derived from a different
animal. Hence, in the statistical analysis, the n-value (3 or 4)
for eachgroup relates to different animals. The signiﬁcanceof
differences between experimental groups (i.e., P! 0.05)
was estimated by applying ANOVA.
Results
SYNOVIUM-DERIVED PROGENITOR CELLS CULTURED
UNDER 2D AND 3D CONDITIONS
After isolation from the synovium of adult bovine joints,
cells were cultured on plastic dishes in 10% serum-
containing medium for expansion. At passage one (cultured
for 1 week), RNA was extracted from a portion of the cells
as a 2D culture control. The remaining cells were cast within
alginate disks for 3D culture and cultured for up to 4 weeks
in medium containing 10% serum. Expression of chondro-
cyte-speciﬁc genes, aggrecan and collagen type II, was
examined by real-time PCR. The activity of these two genes
was found to be induced with time in 3D culture compared
to the cells remaining attached to culture plates (Fig. 1). This
indicates that synovium-derived progenitor cells have
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Fig. 1. Comparison of gene expression by synovium-derived
progenitor cells cultured under 2D and 3D conditions. Bovine
synovial cells from passage one were collected and used as a 2D
control while the remaining cells were cultured in alginate disks for
up to 4 weeks in DMEM containing 10% FBS. The expression levels
of collagen type II and aggrecan mRNA were measured by real-time
PCR (nZ 3, error bars: SD). The values were normalized to 2D
control samples. Abbreviations used: WKZ week; DZ dimension.a chondrogenic potential when cultured under 3D conditions.
The expression of aggrecan mRNA reached a plateau at
2 weeks and kept almost the same level up to the 4th week of
culture (Fig. 1). In contrast, the collagen type II message did
not reach a plateau after a 4-week culture period (Fig. 1).
Since the culturemedium contained 10% serum, the effect of
individually added growth factors could not be monitored
clearly under this culture condition. Therefore, in the
following experiments, the culture medium was changed to
a serum-free, deﬁned medium, and growth factors known to
induce chondrogenic activity were then introduced.
MICROMASS CULTURE OF SYNOVIUM-DERIVED
PROGENITOR CELLS
An alternative method to grow chondrogenic precursor
cells under 3D conditions is the micromass culture 9,14,28.
High concentrations of cells (400,000 per 20 ml drop) were
plated and then overlaid with serum-free medium contain-
ing different growth factors: TGF-b1, TGF-b2, TGF-b3, and
BMP-2 (each at 20 ng/ml). After 1 week in culture, the
gene-expression activities of aggrecan and collagen type II
were monitored using real-time PCR [Fig. 2(A)]. Cells
treated with BMP-2 expressed the highest levels of
aggrecan and collagen type II mRNA. TGF-b1-treated cells
expressed the highest level of aggrecan mRNA among the
TGF-b’s. Interestingly, the expression level of collagen type II
mRNA in the TGF-b-treated cells was lower than that in
untreated control samples, indicating that TGF-b’s inhibit
the expression of this chondrocyte-speciﬁc gene in
synovium-derived progenitor cells. The relative induction
of aggrecan mRNA was much higher than that of collagen
type II in the micromass culture system. All the samples
treated with growth factors stained intensely with alcian
blue (GAG synthesis) [Fig. 2(B)], there being no obvious
differences between these. Dexamethasone (108 M)
inhibited not only the serum-dependent chondrogenic effect
[control, Fig. 2(A)] but also the BMP-2-induced response
(Fig. 3). Hence, this agent was excluded from subsequent
experiments.
DOSE-DEPENDENTEFFECTSOFBMP-2ONGENEEXPRESSION
BY THE SYNOVIUM-DERIVED PROGENITOR CELLS
Because BMP-2 showed the highest activity among the
growth factors, it was selected as a chondrogenic agent in
the rest of the experiments using alginate cultures.
Dosage-dependency of BMP-2 effects was examined by
measuring the expression level of chondrocyte-speciﬁc
genes (Fig. 4). Synovium-derived precursor cells, as well
as chondrocytes, cultured in alginate disks, were kept in
serum-free medium with different concentrations of BMP-2
(0, 10, 50, and 200 ng/ml). After 1 week in culture, these
cells were collected and real-time PCR was performed.
The expression level of Sox9, a transcriptional activator of
the aggrecan and collagen type II genes, was steadily
increased by BMP-2 up to 50 ng/ml, where it reached
a plateau. The maximal induction was approximately 10
times greater than in untreated samples. The maximal
expression level of Sox9 mRNA in synovium-derived
progenitor cells was roughly 4 times lower than that in
chondrocytes cultured under the same condition (data not
shown). Even though Sox9 expression reached a plateau
at 50 ng/ml of BMP-2, aggrecan and collagen type II
mRNA levels continued to increase over the concentration
range tested (Fig. 4). When comparing synovium-derived
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Fig. 2. (A) Collagen type II and aggrecan gene expression upon treatment of synovium-derived progenitor cells with different growth factors
under micromass culture conditions. Cells from synovial membrane were seeded in 24-well culture plates at high density (2! 107 cells/ml).
Cell culturing was performed in serum-free medium with different growth factors (TGF-b1, -b2, -b3 and BMP-2) at 20 ng/ml. After 1 week, RNA
from cells was extracted and gene-expression levels were analyzed by real-time PCR (nZ 3, error bars: SD). Values were normalized to non-
treated samples. (B) Alcian blue staining of micromass cultures grown in the presence of different growth factors for 1 week.progenitor cells with chondrocytes, the maximal expression
levels were two times lower for aggrecan and 30 times
lower for collagen type II (not shown).
mRNA RATIO OF COLLAGENS TYPE II/TYPE I
For additional comparison, chondrocytes and synovium-
derived progenitor cells were cultured in alginate disks for 2
weeks in serum-freemedium.Collagen type I expressionwas
measured and the expression ratio between collagen type I
and type II was compared bymeans of real-timePCR (Fig. 5).
In the chondrocytes, the expression of collagen type II mRNA
was much higher than that of collagen type I, demonstrating
a ratio of col II/col I of 1700:1. In contrast, the expression of
collagen type I was much higher than that of collagen type II
mRNA in the synovium-derived progenitor cells. When the
latter cells were treated with BMP-2, the ratio of col II/col I
increased continuously with the concentration of BMP-2.
However, even at the highest concentration of BMP-2(200 ng/ml), the ratio was still much lower (approximately
1:20) compared to that of the chondrocytes.
GAG CONTENT MEASUREMENTS
Cells were cultured in the alginate disks for 2 and 4 weeks
in the serum-free medium condition with or without 50 ng of
BMP-2, and the GAG synthesis was measured (Fig. 6).
Among 2-week cultures, there was little difference between
control and BMP-2-treated samples. However, a signiﬁcant
difference was seen in the 4-week cultured samples. The
GAG content in the BMP-2-treated samples was approxi-
mately 2.3 fold higher than in the control.
CELL MORPHOLOGY AND IMMUNOHISTOCHEMISTRY
Synovium-derived progenitor cells in alginate disks had
a rounded form (Fig. 7). Moreover, immunohistochemistry
showed that synovial cells incubated with 200 ng/ml BMP-2
532 Y. Park et al.: Chondrogenic differentiation of synovial cellsexpressed collagen type II protein (strong staining reaction),
whereas cells cultured in the absence of BMP-2 exhibited
little collagen II staining (Fig. 8).
Discussion
One of the advantages of using synovium as a cell source
for cartilage repair is that this tissue has the potential of self-
regeneration after removal from synovial joints. Moreover, it
is well known from joint development studies and ontogenetic
processes that the precursors for articular cartilage, menis-
cus and synovial tissue within the joint originate from
the same precursor cell pool29. It thus may be advantageous
to recruit cells for repair from this (ontogenetically) early
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Fig. 3. mRNA expression levels for Sox9 (A), aggrecan (B) and
collagen type II (C) in the absence and presence of dexametha-
sone (108 M). The data reveal this agent to have a profound
inhibitory effect on each of these activities, both in control cultures
(serum alone) and in cultures stimulated with BMP-2 (50 ng/ml).
Incubation period: 1 week. Mean values (GSD) for three experi-
ments are represented.chondrogenic precursor cell pool, a remaining portion of
which seems to persist in the adult organism as a fraction of
the heterogenous cell population within the synovial tissues.
These chondrogenic precursor cells seem to preserve
a lifelong high potential for proliferation and for chondroge-
nic differentiation activities. Moreover, they may retain the
capacity to transform into joint-speciﬁc chondrocytes21,30
and other mesodermally derived differentiated cells26.
In this study, we present evidence that synovium-derived
progenitor cells cultured under 3D conditions and treated
with BMP-2 exhibit chondrogenic differentiation activities by
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Fig. 4. Dose-dependent effects of BMP-2 on gene expression by
synovium-derived progenitor cells in 3D culture. Synovium-derived
progenitor cells in alginate disks were cultured for 1 week with
different concentrations of BMP-2: 0, 10, 50, and 200 ng/ml. The
mRNA levels of chondrocyte-speciﬁc genes, i.e., Sox9, aggrecan,
and collagen type II were monitored by real-time PCR (nZ 4, error
bars: SD). The values were normalized to untreated samples under
the same conditions.
533Osteoarthritis and Cartilage Vol. 13, No. 6expressing chondrocyte-speciﬁc genes such as Sox9,
collagen type II and aggrecan. Additionally, these cells
begin to accumulate GAG and to express collagen type II
protein when treated with BMP-2.
Interestingly, the expression of collagen type II was
suppressed when these progenitor cells were treated with
TGF-b’s as compared to non-treated control samples,
whereas cells treated with BMP-2 showed higher transcrip-
tional activation for collagen type II [except in the presence of
dexamethasone, which inhibited this effect to a measurable
degree (Fig. 3)]. These results contradict those of Nishimura
et al.11, who reported higher expression of collagen type II in
rabbit synovial cells treatedwith TGF-b1. These investigators
used tissue explants and cell aggregates for culturing
(derived fromanother species); they did not deal with isolated
individual cells under 3D culturing conditions. Similarly in
a study by De Bari et al.21, synovial chondrogenic precursor
Chondrocyte Synovium-derived progenitor cell
0 0 10 50 200
ng/ml BMP-2
Fig. 5. Expression ratio of collagen type II to collagen type I in
chondrocytes and synovium-derived progenitor cells, respectively.
Chondrocytes and synovium-derived cells treated with different
concentrations of BMP-2 (0, 10, 50, and 200 ng/ml) were cultured in
alginate disks in serum-free medium for 2 weeks. The expression
levels of collagen type II and type a1(I) mRNAs were determined by
real-time PCR. The relative ratio Col II/Col I was calculated by
comparing the Ct (cycle of threshold) of the samples (nZ 3, error
bars: SD).
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Fig. 6. Measurement of GAG contents in synovial cell cultures.
Synovium-derived progenitor cells were cultured in alginate disks in
serum-free medium with or without BMP-2 (50 ng/ml) for up to 4
weeks. GAG contents were measured using the Blyscan kit. The
amount of GAG was calculated using a standard curve based on
pure chondroitin sulfate (nZ 3, error bars: SD).cells of human origin were not cultured individually under 3D
conditions. Nevertheless, the experimental set-up adopted
by the latter authors corresponded more closely to our own,
particularly with respect to the micromass culturing con-
ditions. It is noteworthy that the reactivity of synovial
chondrogenic progenitor cells differ signiﬁcantly between
species,with that for thehumanpopulationbeingmoreakin to
that for cells of bovine than of rabbit origin. Moreover, under
explant conditions in the presence of an extracellular matrix
and of other cell types, cell reactivity and responsiveness to
signaling substances most likely differ greatly.
Since BMP-2 demonstrated the highest chondrogenic
activity in our experiments, this growth factor was thus used
for the rest of the experiments in this study. There is much
evidence in the literature that BMP-2 promotes chondro-
genesis by various mechanisms: mesenchymal chondro-
genesis2,31, periosteal callus formation32, and modulation of
chondrocyte proliferation33. Moreover, BMP-2 is known to
induce the formation not only of new cartilage, but also of
bone tissue34, thus demonstrating a true capability of BMP-2
to induce both chondrogenic and osteogenic pathways in
appropriate precursor cells under speciﬁc biomechanical
microenvironmental conditions. In this light, one of the
important aspects of our experiments has been the induction
of Sox9 expression by BMP-2. Sox9 is a transcriptional
activator that binds to the promoters and activates transcrip-
tion of collagen type II and aggrecan35,36. Induction of Sox9
by BMP-2 in synovium-derived progenitor cells showed
that these cells have indeed a chondrogenic potential and
are predetermined to become chondrocytes. Over-expres-
sion of Sox9 has been reported to be associated with the
expression of chondrocyte-speciﬁc genes such as collagen
type II and aggrecan, which both play important roles in the
chondrogenic differentiation process31.
The described dosaging experiments revealed that the
expression of Sox9 mRNA reached a maximum at 50 ng/ml
BMP-2 and remained constant up to 200 ng/ml. In contrast,
the expression of collagen type II and aggrecan still had not
achieved plateau values and thus may be further stimulated
at higher concentrations of BMP-2. This showed that the
expression levels of collagen type II and aggrecan mRNA do
not depend exclusively on the expression of Sox9. One of the
reasons may be that the expression of collagen type II and
aggrecan are regulated by at least two different pathways.
Sox9 or other transcriptional factors, induced by BMP-2, may
increase the expression of collagen-speciﬁc extracellular
matrix genes indirectly by binding to the respective promoters
as a trans-acting element31. In addition to this, the BMP-2-
signaling pathway may lead directly to over-expression via
Smad signaling37 and via an enhancer sequence on the
collagen type II promoter. However, most likely other
activation mechanisms are involved when we consider and
compare the gene-expression levels of synovium-derived
progenitor cells with those of chondrocytes. Even though
mRNA expression levels of cartilage-speciﬁc genes were
much higher in BMP-2-treated compared to non-treated
synovial cells, theywere still considerably lower than those in
chondrocytes. The mRNA level of Sox9 in BMP-2-treated
synovial cells was 4 times lower than the corresponding
expression levels in chondrocytes, that of aggrecan was 2
times lower, and that of collagen type II was 30 times lower.
BMP-2-treatment alone of synovial cells was thus not
sufﬁcient to attain gene activity levels comparable with
chondrocytes in vitro.
When we looked at the post-translational cell activities, the
GAG levels after a 4-week culture period indicated that
measurable amounts appeared in the extracellular matrix
534 Y. Park et al.: Chondrogenic differentiation of synovial cellsFig. 7. Light micrographs illustrating synovium-derived chondro-
genic precursor cells cultured for 4 weeks in control medium (A), in
medium containing 50 ng/ml BMP-2 (B), and in medium containing
200 ng/ml BMP-2 (C). Under all three conditions, the chondrogenic
precursor cells show a transformation into chondrocyte-like cells
with lacuna formation. Under the control conditions, the cellonly after a very long time, even though aggrecanmRNAwas
over-expressed from the beginning of the culturing period. In
contrast, the cellular morphology showed that cells in the
alginate disks rounded up to a chondrocytic phenotype and
started to express the collagen type II protein after 1 week in
culture when treated with BMP-2 (as evidenced by the
immunohistochemistry experiments).
Attempts to engineer cartilage tissue in vitro from stem
cells aim at the generation of a hyaline extracellular matrix.
The major organic components of the extracellular cartilage
matrix are aggrecan and collagen type II38. In particular,
collagen type II is the major component in the cartilage
among the different ﬁbrillar and ﬁbril-associated collagens,
implying that collagen type II should be the major protein
produced by the cells. In this study, it was found that
chondrocytes express the collagen type II mRNA at a ratio of
1700:1 with type I collagen mRNA. However, synovium-
derived progenitor cells in alginate without treatment with
BMP-2 showed a ratio of 6! 106. When cells were treated
with 200 ng/ml BMP-2, the expression ratio increased to
0.053. Even though this ratio was thus signiﬁcantly improved,
it still is too low compared to that of chondrocytes. It will thus
be necessary not only to further improve the expression
levels of collagen type II from synovium-derived precursor
cells, but also to inhibit the expression activities for collagen
type I (as was suggested by the use of interferon39).
Bovine synovium-derived chondrogenic precursor cells
showed differential responses to different growth factors and
it can be assumed that these cells are predetermined to the
chondrogenic differentiation pathway when compared to
other types of stem cells. Even though BMP-2, a potent
chondrogenic agent for synovium-derived progenitor cells,
can turn on the chondrogenic pathway in the appropriate
chondrogenic precursor cell pool, these cells still express
ﬁbroblastic characteristics under in-vitro conditions. Turning
off the ﬁbroblastic characteristics will be one of the main
future aims of in-vitro cartilage engineering concepts. The
synovium-derived progenitor cells cultured within alginate
discs clearly rounded up (Fig. 7) and increased in size. This
differentiation process could proceed further, with fully-
ﬂedged hypertrophic chondrocytes being ultimately formed.
And these terminally differentiated chondrocytes could, of
course, begin to mineralize their extracellular matrix. Obvi-
ously, this process would not be desired in the context of
tissue engineering, and future effortsmust therefore bemade
to arrest chondrocyte differentiation during an early hyper-
trophic phase. However, the precise extent of the hypertro-
phic differentiation achieved in the present study was not
ascertained. Nevertheless, this report suggests that synovial
cells may be a possible and useful source of chondrogenic
progenitor cells for future tissue engineering applications.
population is of a relatively smaller size and cells frequently remain
collapsed within the lacunae formed within the alginate material.
The lacunar rims remain faintly stained or unstained with Toluidine
Blue O. In the cell cultures supplemented with BMP-2, the cells
grow to signiﬁcantly larger sizes and volumes, and the population
differentiates into a hypertrophic type of chondrocyte. The cells
more rarely remain collapsed within the lacunae and the lacunar
rims of the alginate generally stain intensely with Toluidine Blue O.
However, the staining intensity varies considerably throughout the
tissue blocks. The number of cells per volume (cellularity) under all
three conditions appears very similar. Toluidine Blue O staining,
semi-thin sections (1 mm). BarsZ 20 mm.
535Osteoarthritis and Cartilage Vol. 13, No. 6Fig. 8. Immunohistochemistry for collagen type II. Synovial cells were cultured in alginate disks with or without BMP-2 for 2 weeks. Cells were
then ﬁxed and processed for parafﬁn section production (control tissue used: adult bovine articular cartilage). Parafﬁn sections (5 mm) were
incubated with antibody against bovine collagen type II. Secondary antibody tagged with horseradish peroxidase was used for visualization.
(A) Cartilage control tissue without primary antibody. Negative staining result. (B) Cartilage control tissue with a primary antibody against
collagen II. Positive staining reaction of chondrocytes. CC D: Synovial cells incubated in the absence (C) and in the presence (D) of BMP-2
(200 ng/ml) and treated with primary antibodies against collagen II. Both sections show scattered positive chondrocyte staining. The intensity
of the staining appears somewhat higher in the BMP-2-treated group than in the untreated group. BarsZ 100 mm.Acknowledgement
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